Latest News Releases 10 April

New candidate genes which could be responsible for deafness have been identified.

The 2025 MRS International Risk Conference will take place in Boston, Massachusetts from July 24 to 26, 2025. Hosted by the Sawyer Business School of Suffolk University, the conference welcomes submissions from scholars worldwide on all aspects of risks and capital markets. The event will also feature an AI and Climate Risk Forum at MIT in the afternoon on July 26th. The China Finance Review International (CFRI), Sawyer Business School of Suffolk University, and Modern Risk Society (MRS) co-organize this conference. Our sponsors include the MIT Environmental Solutions Initiative (ESI), the Global Association for Risk Professionals (GARP), and the Rosenberg Institute for East Asian Studies. This conference was known as the “CFRI & CIRF Conference”. The conference submission deadline is February 10th, 2025, Eastern Time.

At the opening of the World Congress on Osteoporosis, Osteoarthritis & Musculoskeletal Diseases in Rome, Italy, on April 10th, the International Osteoporosis Foundation (IOF) honoured Professor Atsushi Suzuki, Chair of Endocrinology, Diabetes, and Metabolism at Fujita Health University School of Medicine, Japan, with the IOF President’s Award. The esteemed award recognizes individuals for their significant and enduring contributions to advancing the mission of the IOF, through furthering one or more of the Foundation's mission statements and/or goals.

A new University of British Columbia study finds that persistently isolated older Canadian women are more likely to fall short of recommended fruit and vegetable intake, leading to poorer overall diet quality.

A new, error-corrected method for detecting cancer from blood samples is much more sensitive and accurate than prior methods and may be useful for monitoring disease status in patients following treatment, according to a study by Weill Cornell Medicine and New York Genome Center investigators. The method, based on whole-genome sequencing of DNA, also represents an important step toward the goal of routine blood test-based screening for early cancer detection.

Researchers have developed a simple and cost-effective blood test capable of detecting Parkinson’s disease long before symptoms emerge, comparing the current state of diagnosing neurodegenerative diseases to the fight against cancer 50 years ago—when most cases were identified too late for effective treatment. The test quantifies specific RNA fragments in the blood, focusing on a repetitive RNA sequence that accumulates in Parkinson’s patients and a parallel decline in mitochondrial RNA, which deteriorates as the disease progresses. By measuring the ratio between these biomarkers, the test offers a highly accurate, non-invasive, rapid  and affordable diagnostic tool, providing hope for early interventions and treatments that could change the course of the disease.